Foghorn Therapeutics Inc.

Ownership Transactions Reported by 24 Insiders

Symbol
FHTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
500 Technology Square, Suite 700, Cambridge, MA

There are no Buy or Sell transactions made by insiders since 10/18/2024

Foghorn Therapeutics Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Cigall Kadoch Director $29.9M Aug 31, 2022
Flagship Pioneering Inc. 10%+ Owner $20M May 22, 2024
Adrian Gottschalk Chief Executive Officer, Director $3.62M Apr 25, 2025
Carl Decicco Chief Scientific Officer $3.1M Dec 9, 2021
Anna Rivkin Chief Business Officer $1.71M Jan 22, 2025
Steven F. Bellon Chief Scientific Officer $1.58M Jan 22, 2025
Fanny Cavalie Chief Strategy/Bus Ops Officer $1.05M Jun 21, 2024
Allan Reine Chief Financial Officer $719K Jan 16, 2024
Michael LaCascia Chief Legal Officer $551K Jan 22, 2025
Alfonso Quintas Cardama Chief Medical Officer $546K Jan 22, 2025
Kristian Humer Chief Financial Officer $524K Jan 22, 2025
Carlos Costa Chief People Officer $503K Jan 22, 2025
Neil Gallagher Director $208K May 1, 2025
Stuart Duty Director $208K May 1, 2025
Samuel Agresta Chief Medical Officer $184K Sep 11, 2023
Ian F. Smith Director $120K Jun 17, 2025
Thomas J. Lynch Jr. Director $120K Jun 17, 2025
Douglas G. Cole Director $120K Jun 17, 2025
B. Lynne Parshall Director $120K Jun 17, 2025
Simba Gill Director $120K Jun 17, 2025
Scott Biller Director $120K Jun 17, 2025
Michael Mendelsohn Director $120K Jun 17, 2025
Adam Koppel Director $88.3K Dec 29, 2024
Flagship Pioneering Fund VII General Partner LLC 10%+ Owner May 22, 2024

Recent Insider Transactions by Companies or Individuals for Foghorn Therapeutics Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.